|
'''Vamicamide''', also known as FK-176 or Urocut, is a ] (mAChR) antagonist that was developed by ] (now part of ]) for the treatment of ] and ].<ref name = "PatSnap"/> This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters,<ref name="Yamamoto_1995">{{cite journal | vauthors = Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M | title = Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency | journal = The Journal of Urology | volume = 154 | issue = 6 | pages = 2174–8 | date = December 1995 | pmid = 7500484 | doi = | url = }}</ref> vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the New Drug Application (NDA) or Biologics License Application (BLA) phase in Japan.<ref name = "PatSnap">{{cite web | title = Vamicamide | url = https://synapse.patsnap.com/drug/eaf5bdd08c71489181d6c8f1bc01a636 | work = PatSnap }}</ref> |
|
'''Vamicamide''', also known as FK-176 or Urocut, is a ] (mAChR) antagonist that was developed by ] (now part of ]) for the treatment of ] and ].<ref name = "PatSnap"/> This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters,<ref name="Yamamoto_1995">{{cite journal | vauthors = Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M | title = Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency | journal = The Journal of Urology | volume = 154 | issue = 6 | pages = 2174–8 | date = December 1995 | pmid = 7500484 | doi = | url = }}</ref> vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the ] (NDA) phase in Japan.<ref name = "PatSnap">{{cite web | title = Vamicamide | url = https://synapse.patsnap.com/drug/eaf5bdd08c71489181d6c8f1bc01a636 | work = PatSnap }}</ref> |
